Intellia Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Intellia Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2835 — In Vitro & In Vivo Diagnostic Substances
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Cambridge
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- NTLA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001652130
- EIN
- 36-4785571
Board of directors
-
Brian Goff · DirectorSince 2024
-
Frank Verwiel · DirectorSince 2023
- Since 2023
-
Georgia Keresty · DirectorSince 2023
-
Jesse Goodman · DirectorSince 2023
-
John F. Crowley · DirectorSince 2023
-
John M. Leonard · Director · President and CEOSince 2023
-
Muna Bhanji · DirectorSince 2023
-
William J. Chase · DirectorSince 2023
Chief executives
John M. Leonard
· President and CEO
Dates unknown
Director election results
Annual meeting of June 9, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
78.6%
Board connections
8 of this board's directors also sit on 13 other boards.
- via Brian Goff
- via Muna Bhanji
- via Fred E. Cohen
- via Muna Bhanji
- via John F. Crowley
- via William J. Chase
- via John M. Leonard
- via Fred E. Cohen
- via Fred E. Cohen
- via Georgia Keresty
- via Jesse Goodman
- via Fred E. Cohen
- via Muna Bhanji
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $1,402,500
- 1 purchase by 1 insider
- Sold, last 12 months
- $2,173,202
- 19 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 21, 2026 | John M. Leonard Director, Officer (President and CEO) | Open-market sale | −2,785 | $13.00 | $36,205 |
| Aug 20, 2026 | John M. Leonard Director, Officer (President and CEO) | Open-market sale | −19,890 | $12.60 | $250,614 |
| Jul 22, 2026 | Dulac Edward J III Officer (EVP, Chief Financial Officer) | Open-market sale | −8,111 | $11.25 | $91,249 |
| Jul 2, 2026 | Dulac Edward J III Officer (EVP, Chief Financial Officer) | Open-market sale | −4,677 | $18.00 | $84,186 |
| Jul 1, 2026 | Dube Michael P Officer (VP, Chief Accounting Officer) | Open-market sale | −2,641 | $16.78 | $44,316 |
| Jun 9, 2026 | Frank Verwiel Director | Grant or award | +9,200 | — | — |
| Jun 9, 2026 | Georgia Keresty Director | Grant or award | +9,200 | — | — |
| Jun 9, 2026 | Jesse Goodman Director | Grant or award | +9,200 | — | — |
| Jun 9, 2026 | Brian Goff Director | Grant or award | +9,200 | — | — |
| Jun 9, 2026 | Fred E. Cohen Director | Grant or award | +9,200 | — | — |
| Jun 9, 2026 | William J. Chase Director | Grant or award | +9,200 | — | — |
| Jun 9, 2026 | Muna Bhanji Director | Grant or award | +9,200 | — | — |
| Mar 2, 2026 | BASTA JAMES Officer (EVP, General Counsel) | Open-market sale | −1,211 | $13.78 | $16,688 |
| Mar 2, 2026 | Clark Eliana Officer (EVP, Chief Technical Officer) | Open-market sale | −607 | $13.78 | $8,364 |
| Mar 1, 2026 | John M. Leonard Director, Officer (President and CEO) | Grant or award | +156,400 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.